Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome
Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
OPI | Ann: Change of Company Name and Address | 14/10/09 | 0 | 612 | |||
|
|||||||
OPI | Ann: Change of Director's Interest Notice | 14/10/09 | 0 | 454 | |||
|
|||||||
OPI | Ann: Change of Director's Interest Notice | 14/10/09 | 0 | 432 | |||
|
|||||||
OPI | Ann: Change of Director's Interest Notice | 13/10/09 | 0 | 488 | |||
|
|||||||
OPI | Ann: Appendix 3B | 13/10/09 | 0 | 399 | |||
|
|||||||
OPI | Ann: Consolidation of Capital | 12:31 | 0 | 364 | |||
|
|||||||
OPI | Ann: Change in substantial holding (604 Updated) | 30/09/09 | 0 | 346 | |||
|
|||||||
OPI | Ann: Appendix 3Z | 30/09/09 | 0 | 319 | |||
|
See All Discussions